Garon EB, Hellmann MD, Costa EC, et al. Five-year long-term overall survival for patients with advanced NSCLC treated with pembrolizumab: Results from KEYNOTE-001. ASCO Annual Meeting 2019, abstract LBA9015.
Gaat u naar ESMO, bezoek het ESMO in Oranje diner
sep 2019 | Borstkanker, Immuuntherapie, Maag-darm-leveroncologie, Overig, Uro-oncologie